WordNet

the 20th letter of the Roman alphabet (同)t

PrepTutorEJDIC

tritiumの化学記号

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 急性冠症候群がない患者にでの心筋トロポニン濃度の上昇 elevated cardiac troponin concentration in the absence of an acute coronary syndrome
2. 非心臓手術後の周術期心筋梗塞 perioperative myocardial infarction after noncardiac surgery
3. 収縮能障害による心不全における生存期間の予測 predictors of survival in heart failure due to systolic dysfunction

English Journal

Cardiac troponin I, cardiac troponin-specific autoantibodies and natriuretic peptides in children with hypoplastic left heart syndrome.

Eerola A, Poutanen T, Savukoski T, Pettersson K, Sairanen H, Jokinen E, Pihkala J.Author information Department of Paediatrics, University Hospital of Tampere, Tampere, Finland.AbstractOBJECTIVES: To evaluate serum levels of cardiac troponin I (cTnI), autoantibodies against cardiac troponin (cTnAAbs) and natriuretic peptides during the treatment protocol in children with hypoplastic left heart syndrome (HLHS).
Interactive cardiovascular and thoracic surgery.Interact Cardiovasc Thorac Surg.2014 Jan;18(1):80-5. doi: 10.1093/icvts/ivt430. Epub 2013 Oct 6.
OBJECTIVES: To evaluate serum levels of cardiac troponin I (cTnI), autoantibodies against cardiac troponin (cTnAAbs) and natriuretic peptides during the treatment protocol in children with hypoplastic left heart syndrome (HLHS).METHODS: In a prospective study, we had 18 consecutive children with HLH
PMID 24101702

The Effect of Exogenous Creatine Phosphate on Myocardial Injury After Percutaneous Coronary Intervention.

Ke-Wu D, Xu-Bo S, Ying-Xin Z, Shi-Wei Y, Yu-Jie Z, Dong-Mei S, Yu-Yang L, De-An J, Zhe F, Zhi-Ming Z, Hai-Long G, Zhen-Xian Y, Chang-Sheng M.Author information 1Department of Cardiology, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China.AbstractObjective:To evaluate the effect of exogenous creatine phosphate (CP) on myocardial injury after percutaneous coronary intervention (PCI).Method:Four hundred patients were divided to receive conventional therapy (control group) or 3-day intravenous infusion of CP after PCI (CP group). Levels of creatine kinase MB (CK-MB) and troponin I (TnI) were measured before and on postprocedural day 3.Results:Postprocedural CK-MB and TnI in the CP group were significantly increased compared to the control group. In the CP group, 8.0% and 5.0% of patients had an increase in CK-MB 1 to 3 times and >3 times, respectively, which were significantly lower than that of the control group (19.0% and 9.0%, respectively); 12.0% and 10.0% of patients had an increase in TnI 1 to 3 times and >3 times, respectively, which were significantly lower than that of the control group (21.0% and 18.0%, respectively).Conclusion:Exogenous CP was helpful to reduce myocardial injury after PCI.
Angiology.Angiology.2013 Dec 23. [Epub ahead of print]
Objective:To evaluate the effect of exogenous creatine phosphate (CP) on myocardial injury after percutaneous coronary intervention (PCI).Method:Four hundred patients were divided to receive conventional therapy (control group) or 3-day intravenous infusion of CP after PCI (CP group). Levels of crea
PMID 24368725

Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.

Feldman P, Khanna R.Author information Sophia Therapeutics LLC, 351 West 10th Street, Indianapolis, IN 46202, USA.AbstractChronic neuropathic pain management is a worldwide concern. Pharmaceutical companies globally have historically targeted ion channels as the therapeutic catechism with many blockbuster successes. Remarkably, no new pain therapeutic has been approved by European or American regulatory agencies over the last decade. This article will provide an overview of an alternative approach to ion channel drug discovery: targeting regulators of ion channels, specifically focusing on voltage-gated calcium channels. We will highlight the discovery of an anti-nociceptive peptide derived from a novel calcium channel interacting partner - the collapsin response mediator protein 2 (CRMP2). In vivo administration of this peptide reduces pain behavior in a number of models of neuropathic pain without affecting sympathetic-associated cardiovascular activity, memory retrieval, sensorimotor function, or depression. A CRMP2-derived peptide analgesic, with restricted access to the CNS, represents a completely novel approach to the treatment of severe pain with an improved safety profile. As peptides now represent one of the fastest growing classes of new drugs, it is expected that peptide targeting of protein interactions within the calcium channel complex may be a paradigm shift in ion channel drug discovery.
Neuroscience letters.Neurosci Lett.2013 Dec 17;557 Pt A:27-36. doi: 10.1016/j.neulet.2013.06.057. Epub 2013 Jul 3.
Chronic neuropathic pain management is a worldwide concern. Pharmaceutical companies globally have historically targeted ion channels as the therapeutic catechism with many blockbuster successes. Remarkably, no new pain therapeutic has been approved by European or American regulatory agencies over t
PMID 23831344

Japanese Journal

初めての日本・初めての留学 : TNI学生日本短期留学を語る

スピチャヤー,ピンティップ,ナティー [他]
アジアの友 (497), 15-19, 2012-06-00
NAID 40019394325

A Three-Dimensional FRET Analysis to Construct an Atomic Model of the Actin–Tropomyosin–Troponin Core Domain Complex on a Muscle Thin Filament

MIKI Masao,MAKIMURA Satoshi,SUGAHARA Yasuyuki,YAMADA Ryuta,BUNYA Masashi,SAITOH Takahiro,TOBITA Hidetaka
Journal of Molecular Biology 420, 40-55, 2012-03-00
… Wegenerated single-cysteine mutants in the 167–195 region of Tm and in TnC,TnI, and the β-TnT 25-kDa fragment, and each was attached with an energydonor probe. …
NAID 120004186302

幾何制約付HOGとNFTGによる夜間歩行者検出(実世界センシングとその応用)

前渕啓材,呉海元,和田俊和
電子情報通信学会技術研究報告. PRMU, パターン認識・メディア理解 111(379), 291-296, 2012-01-12
… 安定に消失線を求めるために、路面内の白線等の直線情報に基づいて,ハフ変換とパーティクルフィルタから消失点を検出する方法を導入する.近赤外線画像用のHOG(Ni-HOG)を高速に計算するために、lntegral-Ni-HOG(TNi-HOG)を提案する.消失線とカメラパラメータからINi-HOGの探索位置とサイズを導出でき,高速処理かつ誤検出が抑制することが可能になる.歩行者候補領域の検証段階では、人物輪郭モデルとのハウスドルフ距離を …
NAID 110009482308